Compass raises $80M to take magic mushroom drug toward phase 3

Compass Pathways has raised $80 million to prepare its psilocybin therapy for phase 3 development. The London-based biotech is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression. Psilocybin was studied in the 1960s, but research ground to a halt over the following decades. Teams at academic centers including the […]

Marketing COVID-19 is bad news for new drug launches. Which will suffer most?

The COVID-19 pandemic and the ensuing societal countermeasures are upending operations in many sectors—and biopharma isn’t immune. The current lockdown is not only hurting clinical trial enrollment but also delaying regulatory timelines for drugs nearing a decision. And with tried-and-true, in-person marketing techniques no longer allowed, new launches may also feel the pain—or hold off altogether. Consider Bristol […]

Gilead halts emergency access to COVID-19 contender remdesivir amid ‘overwhelming demand’

Since the early days of the current coronavirus outbreak, Gilead Sciences’ experimental antiviral drug remdesivir has been hailed as a leading hope. That halo has apparently overwhelmed the Big Biotech. Gilead has temporarily stopped granting patients emergency access to remdesivir under compassionate use due to an “exponential increase” in requests over the last few days, […]

Oligomerix to Present at BIO CEO & Investor Conference, TAU2020 Global Conference

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO & […]

Research Drug ‘chaperone’ fends off Alzheimer’s in mice by preventing toxic protein clumping

Alzheimer’s disease has long been associated with the harmful proteins amyloid beta and tau. They clump up in the brain, disrupting neurons and causing memory loss and other symptoms. Researchers at Temple University’s Lewis Katz School of Medicine say they’ve found a new way to prevent amyloid beta and tau from building up in the […]

Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain

“This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans,” wrote Jonathan Kipnis of University of Virginia in Charlottesville. “These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing,” he added. More at: […]

Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease

Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening second skeleton. Regeneron Pharmaceuticals believes it can offer hope: A new treatment reduced new bone growth by 90% in a clinical trial, the company said, a result that could lead to Food and Drug Administration approval. More at:  https://www.statnews.com/2020/01/09/regeneron-drug-reduces-bone-growth-rare-skeletal-disease/